In a video posted to Reddit this summer, Lucie Rosenthal’s face starts focused and uncertain, looking intently into the camera, before it happens. She releases a succinct, croak-like belch. Then, it’s wide-eyed surprise, followed by rollicking laughter. “I got it!” the Denver resident says after what was her second burp ever. “It’s really rocking my…
Parsley Health is now in-network with major insurers nationwide, including UnitedHealthcare, Aetna and Cigna. The post Parsley Health Wins Greater Insurance Coverage for its Functional Medicine appeared first on MedCity News.
After the FDA delayed the approval of MDMA-assisted therapy for PTSD, there’s still a way forward for psychedelic medicines, experts said at HLTH. The post What’s Next for Psychedelic Medicines? appeared first on MedCity News.
Soleno Therapeutics brings Neurocrine Biosciences Vykat XR, a drug commercialized for treating the rare genetic disease Prader-Willi syndrome. This blockbuster prospect complements Crenessity, a Neurocrine drug approved for treating a rare endocrine disorder called congenital adrenal hyperplasia. The post Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug appeared first on MedCity…
In this month’s episode, Senior Reporter Katie Adams explored some of the executive moves, exits and layoffs that recently occurred in the healthcare sector. She also interviewed Dr. Jayne Morgan, who recently became vice president of medical affairs at Hello Heart. The post MedCity Moves Podcast: Recent Hires, Layoffs & an Interview with Dr. Jayne…
More than 900 people in Washtenaw County, Michigan, have been sickened with cyclosporiasis since mid-June. Linda Kim, a public health nurse, has called more than 100 of them. Almost everyone has said the same thing: It’s excruciating, and one of the worst illnesses they’ve experienced. But on a Wednesday in July, she called one man…
Backed by Abundant Venture Partners, company focuses the power of AI on helping health systems prevent overpayments on purchased services
Johnson & Johnson has projected its lung cancer drug Rybrevant could achieve $5 billion in peak revenue. At the recent ASCO annual meeting, J&J executive Joshua Bauml explained his company’s strategy for this drug in lung cancer and beyond. The post J&J’s Growth Strategy in Lung Cancer Borrows From Its Experience in Multiple Myeloma appeared…
Teams will develop a patient-facing clinical AI agentic system capable of autonomously supporting patients with heart failure between healthcare visits
Executives from Imagine360, Verily, BrightInsight, Lantern, and Rhapsody shared their approaches to reducing healthcare costs and facilitating digital transformation. The post Heard at HLTH 2024: Insights from Innovative Healthcare Executives appeared first on MedCity News.